GLP-1 receptor agonists continue to demonstrate efficacy beyond diabetes management. Eli Lilly’s Mounjaro matched older treatments in reducing cardiovascular outcomes and showed promising weight loss benefits in a large clinical trial. Meanwhile, Madrigal Pharmaceuticals inked a potentially $2 billion license deal with CSPC Pharmaceutical for a preclinical oral GLP-1 agonist aimed at combining with its MASH treatment Rezdiffra. These advances illustrate the expanding role of GLP-1-based therapies in metabolic and liver diseases, driven by clinical and commercial momentum.